Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme -- Ignore unavailable to you. Want to Upgrade?

To: Logistics who wrote (4064)	6/11/1998 4:44:00 PM
From: TokyoMex	Read Replies (1) \| Respond to of 8798

You see why SA members pay Mex 30 bucks a month ? Because we share.. and will use the money for good cause,,one of these days,, DIGI STRX IMNR Next one is HDIE and CYPH .. tokyojoes-cafe.com Immune <IMNR.O> signs pact with Agouron <AGPH.O> LA JOLLA, Calif., June 11 (Reuters) - Immune Response Corp said Thursday it signed a pact with Agouron Pharmaceuticals for final development and commercialization of HIV treatment REMUNE worth up to $77 million to Immune Response over two years. REMUNE is an immune-based therapy for the treatment of HIV infection which was discovered by Immune Response and is in phase III clinical trials. The two companies plan to complete development and apply for registration of REMUNE in 1999. Under the agreement Immune Response will make commercial supplies of the drug and Agouron will have exclusive rights to market it in North America, Europe, as well as in certain other countries. Immune Response may receive as much as $77 million over the next two years, including license and milestone payments of $45 million, payments to support development of $18 million, and the purchase of $14 million of Immune Response common stock at a premium to market, the company said in a statement. The two companies will equally share all profits from the commercialization of REMUNE. "We made the decision to aggressively pursue this opportunity with Immune Response after a comprehensive review of clinical data on REMUNE from a number of studies, which convinced us of the unique potential of this product to make a powerful contribution to the treatment of HIV infection and AIDS," said Agouron's President and Chief Executive Peter Johnson. REMUNE is an immune-based therapy, derived from HIV itself, which has been shown to elicit an HIV-specific immune response. 16:38 06-11-98 Copyright 1998 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similiar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. All active hyperlinks have been inserted by AOL.